Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56

Avalon Invest Southern California Develop 56

Xconomy

SEPTEMBER 27, 2016

Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).

Avalon 40

Avalon Funding Startup San Diego 40

Xconomy

JANUARY 29, 2020

Agenda topics include Successful Research & Development Models, What It Takes for Commercialization, and Building a Biotech Ecosystem in San Diego. Speakers include Jay Lichter, CEO of COI Pharma and Managing Director at Avalon Ventures; Ciara Kennedy, CEO of Amplyx; and Kim Kamdar, Partner at Domain Associates. $99

San Diego 79

San Diego Avalon Research Ideas 79

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Avelas plans to use the new funding to advance development of AVB-620, the company’s lead diagnostic agent, for use in breast cancer surgeries, CEO Carmine Stengone told me yesterday. Avalon partner Jay Lichter plans to continue serving as Avelas’ chairman, Stengone said.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

AUGUST 31, 2016

Roger Tsien, a UC San Diego scientist who shared the 2008 Nobel Prize in chemistry for research that led to the development of fluorescent proteins used to illuminate tissue and track biological processes, has died, according to a statement from the university. He compared himself to John C. Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 72

San Diego UCSD Avalon Study 72

Xconomy

JULY 20, 2016

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. It’s a little like what Avalon is doing. We really have a development focus,” Martin told me. “We But it’s structured differently. We outsource everything.

San Diego 40

San Diego Avalon Outsource Development Newsletter 40

Xconomy

SEPTEMBER 30, 2016

Who will break free of the pack of companies developing drugs meant to prevent migraines? —Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.

Avalon 40

Avalon Thousand Oaks Study Startup 40